LOS ANGELES—Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and a leader in real-world applications for AI eye screening, has received the FDA’s 510(k) clearance (K200667) to market its EyeArt autonomous AI System for diabetic retinopathy, a leading cause of blindness among American adults, according to a recent announcement. EyeArt is indicated for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in eyes of adults diagnosed with diabetes who have not been previously diagnosed with more than mild diabetic retinopathy.

Read more